NCT06061536View on ClinicalTrials.gov

Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients.

PHASE2RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

November 2, 2023

Primary Completion Date

December 20, 2024

Study Completion Date

December 30, 2024

Conditions
HIV
Interventions
DRUG

Lipovirtide 10mg

Lipovirtide 10mg+3TC+TDF（LP-80：once a week；3TC+TDF：once daily）；

DRUG

Lipovirtide 40mg

Lipovirtide 40mg+3TC+TDF（LP-80：once a week；3TC+TDF：once daily）；

DRUG

Lipovirtide 60mg

Lipovirtide 60mg+3TC+TDF（LP-80：once every 2 weeks；3TC+TDF：once daily）；

DRUG

DTG

DTG +3TC + TDF（once daily）.

Trial Locations (1)

300000

RECRUITING

Tianjin Second People's Hospital, Tianjin

All Listed Sponsors
collaborator

Chinese Academy of Medical Sciences

OTHER

lead

Shanxi Kangbao Biological Product Co., Ltd.

INDUSTRY